新型头孢菌素CB-181963（CAB-175）对甲氧西林敏感或耐药金黄色葡萄球菌以及糖肽类中介敏感葡萄球菌的体外活性
In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.
作者信息
Huang Vanthida, Brown William J, Rybak Michael J
机构信息
Anti-Infective Research Laboratory, Department of Pharmacy Practice-4148, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI 48201, USA.
出版信息
Antimicrob Agents Chemother. 2004 Jul;48(7):2719-23. doi: 10.1128/AAC.48.7.2719-2723.2004.
We examined the activity of CB-181963, a novel cephalosporin, against methicillin-resistant Staphylococcus aureus (MRSA) (n = 200), methicillin-susceptible S. aureus (MSSA) (n = 50), glycopeptide-intermediate Staphylococcus species (GISS) (n = 47), and VRSA (n = 2) isolates. CB-181963 exhibited MIC profiles similar to those of linezolid against MRSA and GISS; however, activity against MSSA was similar to that of vancomycin. Time-kill study results of investigations of activity against MRSA, MSSA, and GISS at 24 h were as follows: CB-181963 activity = vancomycin activity > linezolid activity (P < 0.001); CB-181963 = quinupristin-dalfopristin = vancomycin > linezolid (P < 0.05); CB-181963 > linezolid (P = 0.003); and CB-181963 = quinupristin-dalfopristin = vancomycin. CB-181963 may provide an alternative treatment for multidrug-resistant staphylococci.
我们检测了新型头孢菌素CB - 181963对耐甲氧西林金黄色葡萄球菌（MRSA，n = 200株）、甲氧西林敏感金黄色葡萄球菌（MSSA，n = 50株）、糖肽类中介葡萄球菌属（GISS，n = 47株）及耐万古霉素金黄色葡萄球菌（VRSA，n = 2株）分离株的活性。CB - 181963对MRSA和GISS的最低抑菌浓度（MIC）谱与利奈唑胺相似；然而，其对MSSA的活性与万古霉素相似。针对MRSA、MSSA和GISS在24小时的活性进行的时间杀菌研究结果如下：CB - 181963活性 = 万古霉素活性 > 利奈唑胺活性（P < 0.001）；CB - 181963 = 奎奴普丁 - 达福普汀 = 万古霉素 > 利奈唑胺（P < 0.05）；CB - 181963 > 利奈唑胺（P = 0.003）；且CB - 181963 = 奎奴普丁 - 达福普汀 = 万古霉素。CB - 181963可能为多重耐药葡萄球菌提供一种替代治疗方法。
Zotero 插件